Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TVRD with free AI briefings, catalyst countdowns, and dilution alerts.

TVRD · Tvardi Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar: financing pressure. About 6.3 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Jul 17, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$15.8M Cash on Hand
6.3mo Cash Runway
Follow TVRD by email Get an email when TVRD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TVRD, unsubscribe in one click. Privacy

📣 What TVRD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
STAT3 Inhibitor C-188-9 Hepatocellular Carcinoma Phase 1/2 · NCT05440708 Recruiting
Aromatase Inhibitor Breast Cancer Phase 1 · NCT05384119 Terminated
Control Squamous Cell Carcinoma of Head and Neck Early Phase 1 · NCT05845307 Withdrawn

Also used in these trials (approved or third-party drugs, not TVRD's own candidates): Atezolizumab, Bevacizumab, Pembrolizumab, Fulvestrant, Palbociclib, Ribociclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TVRD holds $15.8M in cash and short-term investments (as of Jun 30, 2026) and burns about $7.5M/quarter from operations, an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TVRD files for a raise →

👥 Who Owns TVRD

Insiders 7.5% Institutions (76 holders) 16.8% Public and other holders 75.7%
HolderTypeShares% of sharesAs of
Shaheen Wirk
Director · +14,011 options
Insider 439,194 3.29% 2025-04-15
Samuel David Tweardy
10% owner
Insider 315,658 2.36% 2025-07-07
Wallace L Jr Hall
Director · +18,000 options
Insider 246,756 1.85% 2025-04-15

Share count 13,363,391 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TVRD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TVRD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.